Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2001

View Archived Issues

Cypress Bioscience launches genomic program for fibromyalgia research

Amarillo Biosciences reports additional analysis of phase II data in FMS trial

Combination abciximab/reteplase therapy has benefits in MI

Hybrigenics and OGS establish proteomics collaboration

Dusa cleared to begin three phase I/II trials with Levulan for new indications

Synthetic peptide inhibits HIV-1 infection in vitro by activating FPRL1

GSK drops late-stage compound from pipeline

Two compounds enter preclinical development at Serono

Aminoguanidine and aspirin compared for their long-term effects on diabetic retinopathy

S. pneumoniae DNA vaccine encoding PPS4 peptide mimetic induces specific immune response in mice

Binding characteristics and effects on steroid synthesis of two new PBR ligands

EpiGenesis obtains license to Genta antisense patents

Phase I/II clinical trials of StreptAvax commence

Enzon begins phase II trial of Prothecan

Promising results reported from Multikine study in HPV-induced cervical dysplasia

Questcor's Emitasol receives approval in the Czech Republic and Poland

OSI-774 to be tested in combination therapy for NSCLC

Titan and Novartis to conduct further trials of iloperidone prior to submission

First market introduction announced for Zelmac

Recent Japanese patent covers new PPARgamma response element activators

Potential antidiabetic agents presented by Ferring

Antitumor bryostatin analogues synthesized at Leland Stanford

Preparation, telomerase-inhibitory and antitumor activity of new series from Aventis

Potent HIV protease inhibition seen in Abbott valinamide derivatives

Selective lck tyrosine kinase inhibitors and use in T-cell-mediated diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...